Olaparib With Bevacizumab — What Each Drug Does and Why They Are Combined

A BRCA mutation is not always required. In ovarian cancer, the combination is indicated for patients whose tumours are HRD-positive — a broader category that includes BRCA mutations but also other patterns of impaired DNA repair. Your tumour tissue needs to be tested for HRD status to answer this question for your specific cancer. Some patients who test HRD-negative may not be candidates for this particular combination, though other treatment options remain available.

Fatigue is reported with both olaparib and bevacizumab individually, and combining them does not guarantee more fatigue — but it can occur. If your tiredness significantly increases — meaning you cannot manage your usual daily activities — tell your team. Blood tests may find an easily corrected cause such as anaemia, which is a known effect of olaparib, and your team can discuss whether a dose adjustment is needed. Do not reduce tablets or skip infusions without guidance.

Response is monitored through imaging — typically CT scans — and in ovarian cancer, CA-125 blood levels alongside imaging. Your oncologist will explain the monitoring schedule and what they are looking for at each assessment. If you notice new symptoms between scheduled scans — increasing pain, a new lump, or unexplained weight loss — report them to your team rather than waiting. New symptoms between visits are information the team needs promptly.

Cost is a real concern and one worth raising with your treating oncologist and the hospital social worker before your first cycle. Biosimilar versions of bevacizumab are available in India and are widely used in oncology practice; these are generally more affordable than the originator product and carry the same mechanism of action. Manufacturer support programmes may also apply in some cases. Any figure quoted to you is indicative and can change — ask for an itemised breakdown so you can explore each component separately.

Both olaparib and bevacizumab carry risks in pregnancy, and effective contraception is required during treatment and for a defined period after the last dose. The specific duration your team recommends will depend on which drugs are in your regimen. If preserving fertility is something you want to discuss, that conversation needs to happen with your oncologist before treatment starts — and ideally with a fertility specialist if options need to be explored. Do not stop contraception during or after treatment without speaking to your team first.

Targeted therapy infusions, including bevacizumab, are administered as day care at CION centres across Telangana and Andhra Pradesh. Olaparib tablets are taken at home on a schedule your team sets. A CION oncologist can confirm whether the combination is appropriate for your diagnosis and biomarker results, and coordinate response-assessment imaging such as PET-CT with partner imaging centres.